Kyle Guse's most recent trade in Plus Therapeutics Inc was a trade of 297,794 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Plus Therapeutics Inc | Kyle Guse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2025 | 297,794 | 297,794 | - | - | Stock Option (Right to Buy) | |
| Plus Therapeutics Inc | Kyle Guse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Atossa Therapeutics Inc | Kyle Guse | CFO, Gen Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 557,900 | 557,900 | - | - | Stock Option (right to buy) | |
| Atossa Therapeutics Inc | Kyle Guse | CFO, Gen Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 746,667 | 746,667 | - | - | Stock Option (right to buy) | |
| Atossa Therapeutics Inc | Kyle Guse | CFO, Gen Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 850,000 | 850,000 | - | - | Stock Option (right to buy) |